BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a drug discovery company developing breakthrough medicines through AI-enhanced computational chemistry, today announced that it is presenting new mechanistic data on its novel salt-inducible kinase 2 (SIK2) inhibitor program at IMMUNOLOGY2026TM, the 109th annual meeting of the American Association of Immunologists (AAI), taking place April 15–19, 2026, in Boston, Massachusetts. Salt-inducible kinases (SIKs) co
2026 Copyright © News-Matic.com. All Rights Reserved
